Vanda Pharmaceuticals (VNDA) Short-term Investments (2010 - 2026)

Vanda Pharmaceuticals' Short-term Investments history runs 17 years deep, the most recent figure standing at $148.3 million for Q1 2026.

• In Q1 2026, Short-term Investments fell 35.28% year-over-year to $148.3 million; the TTM figure through Mar 2026 stood at $148.3 million (down 35.28% YoY), while the FY2025 annual figure was $179.0 million, down 34.27% from the prior year.
• Short-term Investments came in at $148.3 million for Q1 2026 at Vanda Pharmaceuticals, down from $179.0 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $405.4 million in Q3 2022 to a low of $147.3 million in Q1 2023.
• A 5-year average of $274.1 million and a median of $272.3 million in 2024 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments sank 59.99% in 2023 and surged 82.58% in 2024, its largest moves.
• Vanda Pharmaceuticals' Short-term Investments stood at $331.8 million in 2022, then decreased by 23.92% to $252.4 million in 2023, then rose by 7.88% to $272.3 million in 2024, then plunged by 34.27% to $179.0 million in 2025, then dropped by 17.16% to $148.3 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $148.3 million, $179.0 million, and $223.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison